As genomics-focused pharmacology begins to play a greater role in cancer treatment, next-generation sequencing (NGS) is emerging as a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors. With targeted therapies becoming the new standard of care in oncology, NGS-driven companion diagnostics are widely seen as driving the selection of treatments to optimize patient outcomes in the future.
Compared to traditional methods, NGS offers advantages in accuracy, sensitivity, and speed that has the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, it eliminates the need to order multiple tests to identify the causative mutation.
This multigene approach decreases the time to answer, providing a more economical solution and reducing the risk of exhausting precious clinical samples. In addition, NGS can provide high sensitivity, enabling the detection of mutations present at as little as 5% of the DNA isolated from a tumor sample.
NGS has the potential to change the future of oncology and advance the promise of personalized medicine. We invite you to learn more by examining the resources collected here.
Providing customers with a versatile, scalable, sample-to-report workflowRead Article
Key opinion leaders discuss the ongoing challenges and potential of NGS in oncology testing.Read Interview
University of Melbourne and Illumina Target Diagnosis of Difficult CancersRead Article
The user-friendly "Recommended Links" feature allows you to easily find content and products relevant to cancer and/or a variety of other fields. You can access this option from the top of any illumina.com page.Learn How
NGS can help clinical researchers estimate TMB, identify neoantigens, and study innovative therapies to boost the immune response.Learn More
NGS offers the sensitivity and specificity that clinical researchers need to detect low levels of circulating tumor DNA (ctDNA) in the bloodstream.Learn More
Explore the benefits of NGS and microarrays for analyzing altered methylation patterns and other epigenetic changes in cancer.Learn More